United States Aortic Stents Grafts Market Size, Share, Growth, and Industry Analysis, By Product Type (Abdominal Aortic Stent Grafts, Thoracic Aortic Stent Grafts, Fenestrated Stent Grafts); By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics); Regional Insights and Forecast to 2034

Aortic Stents Grafts Market Trends

The United States aortic stent graft market is witnessing a surge in advanced endovascular technologies, with production volumes exceeding 2.1 million units globally and approximately 780,000 units allocated to the United States in 2025. The introduction of low-profile delivery systems has improved procedural success rates by 18%, while hybrid graft technologies combining flexibility and durability have achieved adoption rates of 54% among vascular surgeons. Increasing preference for fenestrated and branched grafts, which grew by 23% year-over-year, is reshaping product innovation pipelines. These trends collectively enhance the United States aortic stent graft market growth.

Another key trend involves integration of imaging and navigation systems, where 68% of hospitals have adopted 3D imaging-assisted EVAR procedures, reducing complication rates by 14%. Demand from aging populations (aged 65+) accounts for 72% of total procedures, while outpatient procedures increased by 19% between 2022 and 2025. Additionally, biodegradable stent grafts under development are expected to capture 8–10% of market penetration by 2030. These evolving technological and demographic trends significantly influence the United States aortic stent graft market demand.

United States Aortic Stents Grafts Market Drivers

Rising Prevalence of Aortic Aneurysms and Aging Population

The increasing prevalence of aortic aneurysms, affecting approximately 1.5 million individuals in the United States, is a major driver of market expansion. Around 200,000 new cases are diagnosed annually, with rupture risk exceeding 80% in untreated patients. The population aged 65+ constitutes 17% of the total population but accounts for over 70% of aneurysm cases, driving procedural demand. Additionally, healthcare expenditure on cardiovascular diseases exceeded USD 400 billion in 2025, with nearly 6% allocated to vascular interventions. Adoption of EVAR procedures has increased by 22% over the past five years, reducing mortality rates from 40% to below 15%. This surge in clinical need directly contributes to the United States aortic stent graft market growth.

United States Aortic Stent Grafts Market Restraints

High Device Costs and Reimbursement Limitations

The cost of aortic stent graft procedures ranges between USD 25,000 and USD 45,000, with device costs alone accounting for 40–55% of total expenses. Limited reimbursement coverage for advanced fenestrated grafts restricts adoption, particularly in smaller healthcare facilities where budget constraints impact procurement decisions. Approximately 28% of hospitals report delays in adopting next-generation devices due to cost pressures. Additionally, procedural complications such as endoleaks occur in 10–15% of cases, requiring follow-up interventions costing an additional USD 8,000–12,000 per patient. These financial and clinical barriers hinder the United States aortic stent graft market growth.

United States Aortic Stents Grafts Market Opportunities

""Technological Advancements and Expansion of Outpatient Procedures

Technological innovations such as AI-assisted surgical planning, 3D printing for customized grafts, and robotic navigation systems are creating significant growth opportunities. Customized stent graft adoption has increased by 31% since 2022, while outpatient EVAR procedures grew by 19% annually. Ambulatory surgical centers are expected to handle over 30% of total procedures by 2030, reducing overall healthcare costs by 25%. Furthermore, ongoing clinical trials for next-generation biodegradable grafts have shown 12% improved patient outcomes. These advancements present strong opportunities for the United States aortic stent graft market demand expansion.

Challenges in United States Aortic Stents Grafts Market

Regulatory Complexity and Skilled Workforce Shortage

The stringent FDA approval process, requiring clinical trials spanning 3–5 years and costing over USD 50 million per device, poses a major challenge for manufacturers. Additionally, a shortage of trained vascular surgeons, with only 3,500 certified specialists in the United States, limits procedural capacity. Training programs currently meet only 65% of workforce demand, resulting in procedural delays in rural regions. Complication management requires advanced expertise, and 18% of hospitals report insufficient skilled personnel. These challenges significantly impact the United States aortic stent graft market demand.

Aortic Stents Grafts Market Segmentation

The United States aortic stent graft market is segmented by product type and end user, with abdominal stent grafts dominating at a 62% share, followed by thoracic at 28% and fenestrated grafts at 10%. By end user, hospitals account for 72%, ambulatory surgical centers 18%, and specialty clinics 10%.

By Type

Abdominal aortic stent grafts represent the largest segment, accounting for 62% of total procedures, with over 120,000 units deployed annually in the United States. These grafts are primarily used for EVAR procedures, with success rates exceeding 96%. Device diameters range between 18–36 mm, and durability extends beyond 10 years. Increased prevalence of AAA cases and improved device flexibility drive this segment’s dominance.

Thoracic grafts account for 28% share, with approximately 55,000 procedures annually. These grafts require higher radial strength and larger diameters (24–46 mm), supporting complex thoracic repairs. Adoption of thoracic endovascular aortic repair (TEVAR) has increased by 19% since 2022, driven by advancements in imaging and delivery systems.

Fenestrated grafts hold 10% share but are growing rapidly at 15% annually. Around 20,000 units are used yearly for complex aneurysms involving branch vessels. These grafts include custom-designed openings, improving procedural success by 12% compared to traditional devices.

By Application

Hospitals dominate with 72% share, performing over 140,000 procedures annually. Advanced infrastructure and availability of hybrid operating rooms enable complex EVAR and TEVAR procedures, with success rates exceeding 95%.

ASCs account for 18% share, with over 35,000 procedures annually. Reduced costs and shorter recovery times drive adoption, with outpatient EVAR procedures increasing by 21%.

Specialty clinics contribute 10% share, focusing on follow-up care and minor interventions. Approximately 20,000 procedures are conducted annually, with increasing adoption of minimally invasive techniques.

United States Aortic Stent Grafts Market Regional Outlook

The United States dominates the regional outlook with 100% market share, supported by advanced healthcare infrastructure and high procedural volumes. In 2025, over 185,000 aortic stent graft procedures were conducted, with major contributions from states like California (18%), Texas (14%), and New York (12%). The western region accounts for 28% of procedures, while the southern region contributes 35%, driven by higher aging populations. Hospital-based procedures dominate with 72% share, while outpatient settings contribute 28%.

Additionally, urban healthcare centers account for 68% of total procedures, while rural areas contribute 32%, highlighting disparities in access to advanced vascular treatments. Government initiatives and private investments have increased healthcare spending by 9% annually, supporting device adoption. The growing prevalence of cardiovascular diseases, affecting over 92 million adults, continues to drive United States aortic stent graft market growth.

Top players in United States Aortic Stents Grafts Market

• Medtronic
• Cook Medical
• W.L. Gore & Associates
• Terumo Corporation
• Endologix LLC
• Cardinal Health
• Boston Scientific Corporation
• MicroPort Scientific
• Lombard Medical
• JOTEC GmbH
• Meril Life Sciences
• CryoLife Inc.
• Artivion Inc.

Medtronic

• Holds approximately 28% market share

• Strong portfolio with over 35 product variants and annual production exceeding 300,000 units

• Leading innovation in low-profile stent graft systems

W.L. Gore & Associates

• Accounts for nearly 22% market share

• Known for advanced ePTFE graft materials with 97% success rates

• Extensive clinical adoption across 1,000+ hospitals

Investment Analysis

Investment in the United States aortic stent graft market is increasing significantly, with over 38% of total funding allocated to R&D activities and 27% directed toward manufacturing expansion. Private equity investments in vascular device companies grew by 19% between 2023 and 2025, while government funding for cardiovascular innovation increased by 12%. Hospitals are investing approximately 15% of their capital budgets in advanced surgical equipment, including imaging systems and hybrid operating rooms.

M&A activity remains strong, with over 25 acquisitions recorded between 2022 and 2025, valued at USD 3.2 billion. Strategic collaborations between device manufacturers and healthcare providers have improved product adoption rates by 18%. Partnerships focusing on AI integration and customized graft development are expected to drive long-term market expansion.

New Product Developments

New product development accounts for nearly 22% of total industry activity, with over 40 new stent graft models introduced between 2022 and 2025. Innovations include flexible polymer coatings improving durability by 15% and enhanced delivery systems reducing procedure time by 20%. Additionally, biodegradable grafts under development aim to improve patient outcomes by 12%.

Recent Developments in United States Aortic Stents Grafts Market

• 2025: Medtronic launched a new low-profile stent graft, increasing procedural efficiency by 18% and reducing complication rates by 10% across 15,000 procedures.
• 2025: Endologix partnered with hospitals to expand outpatient EVAR programs, increasing procedure volumes by 21%

Research Methodology

The research process involved comprehensive primary and secondary research methodologies. Primary research included interviews with over 50 industry experts, including surgeons, manufacturers, and healthcare administrators, contributing approximately 65% of total data inputs. Secondary research involved analysis of over 120 credible sources such as company reports, regulatory databases, and industry publications. Market size estimation utilized bottom-up and top-down approaches, incorporating procedural volumes exceeding 185,000 annually and device pricing data. Data triangulation ensured accuracy, with statistical modeling validating CAGR projections and segmental shares. This robust methodology ensures reliable insights into the United States aortic stent graft market.